Matthias V. Kopp

Best Publications

• What is precision medicine

  Inke R. König;Oliver Fuchs;Oliver Fuchs;Gesine Hansen;Erika von Mutius

  553
  Citations

• Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases

  Oliver Pfaar;Claus Bachert;Albrecht Bufe;Roland Buhl

  424
  Citations

• The impact of probiotics and prebiotics on the immune system

  Todd R. Klaenhammer;Michiel Kleerebezem;Matthias Volkmar Kopp;Maria Rescigno

  380
  Citations

• Preterm birth and sustained inflammation: consequences for the neonate.

  Unknown

  266
  Citations

• Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma

  M. V. Kopp;E. Hamelmann;S. Zielen;W. Kamin

  230
  Citations

• Polymorphisms in the IL 18 gene are associated with specific sensitization to common allergens and allergic rhinitis.

  Susanne Kruse;Joachim Kuehr;Michael Moseler;Matthias V. Kopp

  186
  Citations

• Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease

  Markus Weckmann;Adam Collison;Jodie L Simpson;Matthias V Kopp

  174
  Citations

• A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.

  C. Rolinck-Werninghaus;H. Wolf;C. Liebke;J. C. Baars

  167
  Citations

• Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement.

  M A Calderon;R Gerth van Wijk;I Eichler;P M Matricardi

  136
  Citations

• Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update

  Johannes Ring;Kirsten Beyer;Tilo Biedermann;Andreas Bircher

  136
  Citations

• Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen.

  C. Rolinck-Werninghaus;M. Kopp;C. Liebke;J. Lange

  127
  Citations

• Perspectives in allergen immunotherapy: 2019 and beyond

  Oliver Pfaar;Ioana Agache;Frédéric de Blay;Sergio Bonini

  121
  Citations

• The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.

  Matthias Volkmar Kopp;Jens Brauburger;Frank Riedinger;Dorothee Beischer a

  115
  Citations

• Guideline on allergen immunotherapy in IgE-mediated allergic diseases

  Unknown

  111
  Citations

• Association of TNF-α with severe respiratory syncytial virus infection and bronchial asthma

  Beena Puthothu;Sibylle Bierbaum;Matthias V. Kopp;Johannes Forster

  107
  Citations

• T2-high asthma phenotypes across lifespan

  Unknown

  102
  Citations

• Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.

  Matthias Volkmar Kopp;Eckard Hamelmann;Meike Bendiks;Stefan Zielen

  98
  Citations

• ARIA guideline 2019: treatment of allergic rhinitis in the German health system.

  Ludger Klimek;Claus Bachert;Oliver Pfaar;Sven Becker

  97
  Citations

• Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial.

  Matthias Griese;Matthias Kappler;Claudia Eismann;Manfred Ballmann

  96
  Citations

• Perspectives in allergen immunotherapy: 2017 and beyond.

  O. Pfaar;S. Bonini;S. Bonini;V. Cardona;P. Demoly

  90
  Citations